{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:01:47Z","timestamp":1761807707196},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,1,14]],"date-time":"2012-01-14T00:00:00Z","timestamp":1326499200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10067-011-1921-0","type":"journal-article","created":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T10:33:53Z","timestamp":1326710033000},"page":"585-594","source":"Crossref","is-referenced-by-count":20,"title":["Managing cardiovascular risk in patients with chronic inflammatory diseases"],"prefix":"10.1007","volume":"31","author":[{"given":"Boulos","family":"Haraoui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,14]]},"reference":[{"key":"1921_CR1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jacc.2009.08.005","volume":"54","author":"RF Redberg","year":"2009","unstructured":"Redberg RF, Benjamin EJ, Bittner V et al (2009) ACCF\/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol 54:1364\u20131405","journal-title":"J Am Coll Cardiol"},{"key":"1921_CR2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","volume":"25","author":"J Genest","year":"2009","unstructured":"Genest J, McPherson R, Frohlich J et al (2009) 2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult\u20142009 recommendations. Can J Cardiol 25:567\u2013579","journal-title":"Can J Cardiol"},{"key":"1921_CR3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829\u2013835","journal-title":"J Am Acad Dermatol"},{"key":"1921_CR4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","volume":"145","author":"S Prodanovich","year":"2009","unstructured":"Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG (2009) Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145:700\u2013703","journal-title":"Arch Dermatol"},{"key":"1921_CR5","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","volume":"107","author":"DH Solomon","year":"2003","unstructured":"Solomon DH, Karlson EW, Rimm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303\u20131307","journal-title":"Circulation"},{"key":"1921_CR6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","volume":"47","author":"LS Tam","year":"2008","unstructured":"Tam LS, Tomlinson B, Chu TT et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls\u2014the role of inflammation. Rheumatology (Oxford) 47:718\u2013723","journal-title":"Rheumatology (Oxford)"},{"key":"1921_CR7","first-page":"36","volume":"30","author":"F Wolfe","year":"2003","unstructured":"Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36\u201340","journal-title":"J Rheumatol"},{"key":"1921_CR8","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685\u20131695","journal-title":"N Engl J Med"},{"key":"1921_CR9","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1161\/01.ATV.0000034543.78801.69","volume":"22","author":"TJ Wang","year":"2002","unstructured":"Wang TJ, Nam BH, Wilson PW et al (2002) Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 22:1662\u20131667","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1921_CR10","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/ATVBAHA.109.190108","volume":"29","author":"KS Stamatelopoulos","year":"2009","unstructured":"Stamatelopoulos KS, Kitas GD, Papamichael CM et al (2009) Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 29:1702\u20131708","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1921_CR11","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735\u20131741","journal-title":"JAMA"},{"key":"1921_CR12","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/jid.2009.112","volume":"129","author":"JM Gelfand","year":"2009","unstructured":"Gelfand JM, Dommasch ED, Shin DB et al (2009) The risk of stroke in patients with psoriasis. J Invest Dermatol 129:2411\u20132418","journal-title":"J Invest Dermatol"},{"key":"1921_CR13","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","volume":"31","author":"NN Mehta","year":"2010","unstructured":"Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31:1000\u20131006","journal-title":"Eur Heart J"},{"key":"1921_CR14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1468-3083.2009.03318.x","volume":"23","author":"J Xiao","year":"2009","unstructured":"Xiao J, Chen LH, Tu YT, Deng XH, Tao J (2009) Prevalence of myocardial infarction in patients with psoriasis in Central China. J Eur Acad Dermatol Venereol 23:1311\u20131315","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1921_CR15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","volume":"58","author":"J Listing","year":"2008","unstructured":"Listing J, Strangfeld A, Kekow J et al (2008) Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667\u2013677","journal-title":"Arthritis Rheum"},{"key":"1921_CR16","first-page":"1196","volume":"30","author":"DJ Watson","year":"2003","unstructured":"Watson DJ, Rhodes T, Guess HA (2003) All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30:1196\u20131202","journal-title":"J Rheumatol"},{"key":"1921_CR17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","volume":"37","author":"F Wolfe","year":"1994","unstructured":"Wolfe F, Mitchell DM, Sibley JT et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481\u2013494","journal-title":"Arthritis Rheum"},{"key":"1921_CR18","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/ard.2009.122226","volume":"69","author":"DH Solomon","year":"2010","unstructured":"Solomon DH, Kremer J, Curtis JR et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920\u20131925","journal-title":"Ann Rheum Dis"},{"key":"1921_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/09546630802225702","volume":"20","author":"RJ Driessen","year":"2009","unstructured":"Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM (2009) Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. J Dermatolog Treat 20:42\u201347","journal-title":"J Dermatolog Treat"},{"key":"1921_CR20","first-page":"1213","volume":"32","author":"LT Jacobsson","year":"2005","unstructured":"Jacobsson LT, Turesson C, Gulfe A et al (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213\u20131218","journal-title":"J Rheumatol"},{"key":"1921_CR21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","volume":"69","author":"MJ Peters","year":"2010","unstructured":"Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325\u2013331","journal-title":"Ann Rheum Dis"},{"key":"1921_CR22","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","volume":"330","author":"J Hippisley-Cox","year":"2005","unstructured":"Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366","journal-title":"BMJ"},{"key":"1921_CR23","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","volume":"165","author":"SP Johnsen","year":"2005","unstructured":"Johnsen SP, Larsson H, Tarone RE et al (2005) Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case\u2013control study. Arch Intern Med 165:978\u2013984","journal-title":"Arch Intern Med"},{"key":"1921_CR24","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/art.23935","volume":"59","author":"Z Nadareishvili","year":"2008","unstructured":"Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F (2008) Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case\u2013control study. Arthritis Rheum 59:1090\u20131096","journal-title":"Arthritis Rheum"},{"key":"1921_CR25","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1001\/archinternmed.2009.394","volume":"169","author":"JS Ross","year":"2009","unstructured":"Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM (2009) Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 169:1976\u20131985","journal-title":"Arch Intern Med"},{"key":"1921_CR26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","volume":"47","author":"VF Panoulas","year":"2008","unstructured":"Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A et al (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:72\u201375","journal-title":"Rheumatology (Oxford)"},{"key":"1921_CR27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","volume":"141","author":"L Wei","year":"2004","unstructured":"Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764\u2013770","journal-title":"Ann Intern Med"},{"key":"1921_CR28","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.23811","volume":"58","author":"F Wolfe","year":"2008","unstructured":"Wolfe F, Michaud K (2008) The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case\u2013control analysis. Arthritis Rheum 58:2612\u20132621","journal-title":"Arthritis Rheum"},{"key":"1921_CR29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","volume":"90","author":"PC Souverein","year":"2004","unstructured":"Souverein PC, Berard A, Van Staa TP et al (2004) Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case\u2013control study. Heart 90:859\u2013865","journal-title":"Heart"},{"key":"1921_CR30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173\u20131177","journal-title":"Lancet"},{"key":"1921_CR31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","volume":"52","author":"S Prodanovich","year":"2005","unstructured":"Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262\u2013267","journal-title":"J Am Acad Dermatol"},{"key":"1921_CR32","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/S0140-6736(00)02222-4","volume":"355","author":"RB Landewe","year":"2000","unstructured":"Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA (2000) Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 355:1616\u20131617","journal-title":"Lancet"},{"key":"1921_CR33","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1002\/art.22255","volume":"54","author":"DH Solomon","year":"2006","unstructured":"Solomon DH, Avorn J, Katz JN et al (2006) Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 54:3790\u20133798","journal-title":"Arthritis Rheum"},{"key":"1921_CR34","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","volume":"156","author":"S Setoguchi","year":"2008","unstructured":"Setoguchi S, Schneeweiss S, Avorn J et al (2008) Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 156:336\u2013341","journal-title":"Am Heart J"},{"key":"1921_CR35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","volume":"116","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116:305\u2013311","journal-title":"Am J Med"},{"key":"1921_CR36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2006.067660","volume":"66","author":"L Carmona","year":"2007","unstructured":"Carmona L, Descalzo MA, Perez-Pampin E et al (2007) All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880\u2013885","journal-title":"Ann Rheum Dis"},{"key":"1921_CR37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/rheumatology\/keh610","volume":"44","author":"S Bernatsky","year":"2005","unstructured":"Bernatsky S, Hudson M, Suissa S (2005) Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44:677\u2013680","journal-title":"Rheumatology (Oxford)"},{"key":"1921_CR38","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/art.27660","volume":"62","author":"M Lunt","year":"2010","unstructured":"Lunt M, Watson KD, Dixon WG, Symmons DP, Hyrich KL (2010) No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62:3145\u20133153","journal-title":"Arthritis Rheum"},{"key":"1921_CR39","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133\u20133140","journal-title":"Circulation"},{"key":"1921_CR40","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1161\/CIRCULATIONAHA.106.179568","volume":"114","author":"RE Kavey","year":"2006","unstructured":"Kavey RE, Allada V, Daniels SR et al (2006) Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114:2710\u20132738","journal-title":"Circulation"},{"key":"1921_CR41","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1002\/art.21932","volume":"54","author":"S Doornum Van","year":"2006","unstructured":"Van Doornum S, Brand C, King B, Sundararajan V (2006) Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 54:2061\u20132068","journal-title":"Arthritis Rheum"},{"key":"1921_CR42","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.284.8.984","volume":"284","author":"CH MacLean","year":"2000","unstructured":"MacLean CH, Louie R, Leake B et al (2000) Quality of care for patients with rheumatoid arthritis. JAMA 284:984\u2013992","journal-title":"JAMA"},{"key":"1921_CR43","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837\u20131847","journal-title":"Circulation"},{"key":"1921_CR44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D'Agostino Sr","year":"2008","unstructured":"D'Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743\u2013753","journal-title":"Circulation"},{"key":"1921_CR45","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","volume":"24","author":"RM Conroy","year":"2003","unstructured":"Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987\u20131003","journal-title":"Eur Heart J"},{"key":"1921_CR46","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","volume":"297","author":"PM Ridker","year":"2007","unstructured":"Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611\u2013619","journal-title":"JAMA"},{"key":"1921_CR47","first-page":"1766","volume":"33","author":"M Soubrier","year":"2006","unstructured":"Soubrier M, Zerkak D, Dougados M (2006) Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol 33:1766\u20131769","journal-title":"J Rheumatol"},{"key":"1921_CR48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5694\/j.1326-5377.2006.tb00239.x","volume":"184","author":"S Doornum Van","year":"2006","unstructured":"Van Doornum S, Jennings GL, Wicks IP (2006) Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 184:287\u2013290","journal-title":"Med J Aust"},{"key":"1921_CR49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ncprheum0178","volume":"2","author":"JT Giles","year":"2006","unstructured":"Giles JT, Post W, Blumenthal RS, Bathon JM (2006) Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2:320\u2013329","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1921_CR50","unstructured":"National Heart, Lung and Blood Institute (2004) The National Cholesterol Education Program: detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). National Heart, Lung and Blood Institute. US Department of Health and Human Services. 10-5-0100"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-011-1921-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-011-1921-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-011-1921-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T21:35:40Z","timestamp":1593552940000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-011-1921-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,14]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1007\/s10067-011-1921-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,14]]}}}